Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related death. Despite advances in chemotherapy and immunotherapy, the prognosis for advanced patients remains poor. The discovery of oncogenic driver mutations, such as anap...
Main Authors: | Yan Xiang, Shiyu Zhang, Xiaoxu Fang, Yingying Jiang, Tingwen Fang, Jinwen Liu, Kaihua Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/10/618 |
Similar Items
-
ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib
by: Jikui Guan, et al.
Published: (2024-01-01) -
NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
by: Elissa Andraos, et al.
Published: (2021-01-01) -
Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
by: Arthur Aubry, et al.
Published: (2019-02-01) -
An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance
by: Adela Patcas, et al.
Published: (2022-02-01) -
Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment
by: Vivek Yadav, et al.
Published: (2024-04-01)